VIR

9.26

2.32% -0.22

Dopo l'orario di chiusura: 9.19 -0.07 -0.76%

Vir Biotechnology Inc (VIR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VIR Giù? Forum Previsione

Precedente Chiudi:

$9.48

Aprire:

$9.61

Volume 24 ore:

2.61M

Relative Volume:

0.82

Capitalizzazione di mercato:

$1.48B

Reddito:

$68.56M

Utile/perdita netta:

$-437.99M

Rapporto P/E:

-2.9268

EPS:

-3.1639

Flusso di cassa netto:

$-396.61M

1 W Prestazione:

-3.04%

1M Prestazione:

+23.96%

6M Prestazione:

+85.20%

1 anno Prestazione:

+32.29%

Intervallo 1D:

$9.12

$9.73

Intervallo di 1 settimana:

$9.12

$10.29

Portata 52W:

$4.155

$10.94

Vir Biotechnology Inc Stock (VIR) Company Profile

Nome

Vir Biotechnology Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

415-906-4324

Indirizzo

1800 OWENS STREET, SAN FRANCISCO, CA

Dipendente

367

Cinguettio

@Vir_Biotech

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

VIR's Discussions on Twitter

Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VIR Vir Biotechnology Inc	9.26	1.48B	68.56M	-437.99M	-396.61M	-3.1639
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Aggiornamento	Raymond James	Outperform → Strong Buy
2025-09-03	Iniziato	Evercore ISI	Outperform
2025-08-27	Aggiornamento	BofA Securities	Neutral → Buy
2024-01-29	Downgrade	JP Morgan	Overweight → Neutral
2023-09-08	Downgrade	BofA Securities	Buy → Neutral
2023-03-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-02-21	Aggiornamento	Goldman	Neutral → Buy
2023-01-27	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Iniziato	SVB Leerink	Outperform
2022-09-09	Iniziato	Morgan Stanley	Underweight
2022-03-03	Aggiornamento	Robert W. Baird	Underperform → Neutral
2021-12-21	Downgrade	Robert W. Baird	Neutral → Underperform
2021-10-25	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-22	Downgrade	Goldman	Buy → Neutral
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-01-27	Downgrade	JP Morgan	Neutral → Underweight
2021-01-20	Reiterato	H.C. Wainwright	Buy
2020-10-05	Iniziato	BofA Securities	Buy
2020-09-14	Aggiornamento	Goldman	Neutral → Buy
2020-09-11	Aggiornamento	JP Morgan	Underweight → Neutral
2020-08-20	Iniziato	Needham	Buy
2020-03-19	Downgrade	JP Morgan	Neutral → Underweight
2020-03-13	Downgrade	Goldman	Buy → Neutral
2020-02-27	Downgrade	Robert W. Baird	Neutral → Underperform
2020-02-04	Downgrade	JP Morgan	Overweight → Neutral
2019-11-14	Iniziato	Robert W. Baird	Neutral
2019-11-05	Iniziato	Barclays	Overweight
2019-11-05	Iniziato	Cowen	Outperform
2019-11-05	Iniziato	Goldman	Buy
2019-11-05	Iniziato	JP Morgan	Overweight

Mostra tutto

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

Mar 14, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 14, 2026

Mar 11, 2026

Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis

Mar 11, 2026

Mar 09, 2026

Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN

Mar 09, 2026

VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union

Mar 09, 2026

Mar 07, 2026

Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat

Mar 07, 2026

Mar 06, 2026

HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat

Mar 06, 2026

Mar 05, 2026

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits

Mar 05, 2026

Vir Biotechnology Names CEO Marianne De Backer as President - The Globe and Mail

Mar 05, 2026

Mar 04, 2026

According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget

Mar 04, 2026

Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView

Mar 04, 2026

Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com

Mar 04, 2026

Vir Biotechnology, Inc. Appoints Marianne De Backer as President - marketscreener.com

Mar 04, 2026

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Mar 04, 2026

VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus

Mar 04, 2026

Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st

Mar 04, 2026

Mar 03, 2026